

Jeffery J Auletta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3120866/publications.pdf>

Version: 2024-02-01

93
papers

2,324
citations

236925

25
h-index

254184

43
g-index

97
all docs

97
docs citations

97
times ranked

3881
citing authors

#	ARTICLE	IF	CITATIONS
1	Return-to-School Practices for Pediatric Hematopoietic Cell Transplantation Recipients during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 54.e1-54.e4.	1.2	2
2	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29384.	1.5	8
3	Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 233-241.	1.2	5
4	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
5	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	1.4	20
6	Buckling up against COVID-19 after CAR T-cell therapy. <i>Blood</i> , 2022, 140, 85-87.	1.4	2
7	Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 696.e1-696.e7.	1.2	7
8	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	1.2	3
9	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	1.2	16
10	Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 133-141.	1.2	20
11	Development of a Quality Improvement Learning Collaborative to Improve Pediatric Sepsis Outcomes. <i>Pediatrics</i> , 2021, 147, .	2.1	43
12	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
13	COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. <i>Journal of Infection</i> , 2021, 82, 329-338.	3.3	150
14	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	1.4	85
15	Metric Development for the Multicenter Improving Pediatric Sepsis Outcomes (IPSO) Collaborative. <i>Pediatrics</i> , 2021, 147, .	2.1	17
16	Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2021, 25, e14041.	1.0	3
17	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. <i>Blood Advances</i> , 2021, 5, 1-11.	5.2	46
18	Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. <i>Stem Cells</i> , 2021, 39, 1506-1519.	3.2	4

#	ARTICLE	IF	CITATIONS
19	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
20	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	4.6	56
21	Refractory Thrombocytopenia Is a Valid Early Diagnostic Criteria for Hepatic Veno-Occlusive Disease in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 546-552.	2.0	8
22	How We Treat Fever and Hypotension in Pediatric Hematopoietic Cell Transplant Patients. <i>Frontiers in Oncology</i> , 2020, 10, 581447.	2.8	2
23	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 596-608.	1.3	29
24	Infection prophylaxis patterns following pediatric autologous hematopoietic stem cell transplantation: A survey of Pediatric Transplant and Cell Therapy Consortium centers. <i>Pediatric Transplantation</i> , 2020, 24, e13821.	1.0	3
25	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
26	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14
27	Successful treatment of steroidâ€refractory gastrointestinal acute graftâ€versusâ€host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28298.	1.5	6
28	Pediatric cancer research: Surviving COVIDâ€19. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28435.	1.5	28
29	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e147-e160.	2.0	37
30	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
31	GCT-25. INNOVATIVE, INTENSIVE IRRADIATION-AVOIDING/MINIMIZING CHEMOTHERAPY FOR HIGH-RISK PRIMARY CENTRAL NERVOUS SYSTEM (CNS) MIXED MALIGNANT GERM CELL TUMORS (HR-MMGCT): A PILOT STUDY AND PROPOSED MULTI-NATIONAL PROSPECTIVE TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii333-iii333.	1.2	0
32	Improving Occupational Performance in Pediatric Hematopoietic Cell Transplant Recipients. <i>American Journal of Occupational Therapy</i> , 2020, 74, 7405205020p1-7405205020p11.	0.3	3
33	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22
34	Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplantâ€associated thrombotic microangiopathy in patients transplanted for sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27912.	1.5	13
35	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
36	Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 594-597.e4.	2.9	5

#	ARTICLE	IF	CITATIONS
37	Transplant Energize Me Patient Outcome (TEMPO): A Quality Improvement Project that Maintains Functional Mobility in Pediatric Patients Admitted for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1779-1785.	2.0	6
38	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. <i>JAMA Pediatrics</i> , 2019, 173, e190081.	6.2	14
39	Tâ€™ing off on posttransplant CMV. <i>Blood</i> , 2019, 133, 777-779.	1.4	3
40	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
41	Related and unrelated donor transplantation for β^2 -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	5.2	48
42	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47
43	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	5.8	41
44	Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1031-1038.	2.0	5
45	The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation. <i>Pediatric Transplantation</i> , 2018, 22, e13139.	1.0	17
46	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
47	Synchronous Central Nervous System Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor of the Kidney: Case Report of a Long-Term Survivor and Review of the Literature. <i>World Neurosurgery</i> , 2018, 111, 6-15.	1.3	6
48	Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 3: Focus on Cardiorespiratory Dysfunction, Infections, Liver Dysfunction, and Delirium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 207-218.	2.0	10
49	70% Ethanol for Decontamination of Central Venous Lines Exposed to Calcineurin Inhibitors. <i>Annals of Pharmacotherapy</i> , 2018, 52, 32-39.	1.9	1
50	Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 337-342.	2.0	8
51	Monozygotic twins diagnosed simultaneously with <sc>RAM</sc> immunophenotype acute myeloid leukemia. <i>Pediatric Transplantation</i> , 2018, 22, e13291.	1.0	4
52	AML: exposed and exploited?. <i>Blood</i> , 2018, 131, 8-10.	1.4	3
53	Related and Unrelated Donor Transplantation for β^2 Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	1.4	1
54	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1342-1349.	2.0	50

#	ARTICLE	IF	CITATIONS
55	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1523-1530.	2.0	13
56	Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26503.	1.5	12
57	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1817-1825.	2.0	27
58	Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents: Part 2—Focus on Ascites, Fluid and Electrolytes, Renal, and Transfusion Issues. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2023-2033.	2.0	17
59	70% Ethanol for Decontamination of Cvl Exposed to Calcineurine Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S287.	2.0	0
60	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	1.4	403
61	Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 658-668.	2.0	23
62	Human leukocyte antigen mismatching and survival after lung transplantation in adult and pediatric patients with cystic fibrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 549-557.e1.	0.8	10
63	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3409-3409.	1.4	0
64	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3410-3410.	1.4	0
65	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
66	Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1674-1676.	1.5	30
67	Emerging Influence of the Intestinal Microbiota during Allogeneic Hematopoietic Cell Transplantation: Control the Gut and the Body Will Follow. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1360-1366.	2.0	42
68	Human Mesenchymal Stromal Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia Activity Following Experimental Allogeneic Bone Marrow Transplantation. <i>Stem Cells</i> , 2015, 33, 601-614.	3.2	76
69	Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation. <i>Journal of Stem Cells and Regenerative Medicine</i> , 2015, 11, 34-43.	2.2	6
70	Febrile Neutropenia. <i>Pediatric Oncology</i> , 2015, , 1-25.	0.5	0
71	Cibmtr Retrospective Analysis Reveals Incidence, Mortality, and Timing of Pneumocystis Jiroveci Pneumonia (PCP) after Hematopoietic Stem Cell Transplantation (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S94.	2.0	1
72	Comparison of Infection Rates Among Acute Leukemia Patients in Remission Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S91-S92.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Role of Early Initiation of Continuous Veno-Venous Hemofiltration (CVVH) for Management of Sinusoidal Obstructive Syndrome (SOS) Following Stem Cell Transplant (SCT). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S188-S189.	2.0	0
74	The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. <i>Immunotherapy</i> , 2012, 4, 529-547.	2.0	49
75	Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy. <i>Immunotherapy</i> , 2012, 4, 1139-1151.	2.0	4
76	Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. <i>Blood</i> , 2012, 119, 1801-1809.	1.4	98
77	Fibroblast Growth Factor-2 Enhances Expansion of Human Bone Marrow-Derived Mesenchymal Stromal Cells without Diminishing Their Immunosuppressive Potential. <i>Stem Cells International</i> , 2011, 2011, 1-10.	2.5	36
78	Human Mesenchymal Stem Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia in Murine Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2011, 118, 1907-1907.	1.4	1
79	The Synthetic Triterpenoid, CDDO-Me, Modulates the Proinflammatory Response to In Vivo Lipopolysaccharide Challenge. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 497-508.	1.2	25
80	Regulation of corneal inflammation by neutrophil-dependent cleavage of keratan sulfate proteoglycans as a model for breakdown of the chemokine gradient. <i>Journal of Leukocyte Biology</i> , 2010, 88, 517-522.	3.3	25
81	Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future Directions. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 891-906.	2.0	39
82	Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1318-1320.	1.5	9
83	Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. <i>Current Opinion in Pediatrics</i> , 2009, 21, 30-38.	2.0	23
84	CpG-Induced IFN γ expands TLR4-specific IL-18 responses in vivo. <i>Cellular Immunology</i> , 2006, 243, 75-82.	3.0	7
85	In vivo and In vitro Regulation of Type I IFN Synthesis by Synergistic Effects of CD40 and Type II IFN. <i>Journal of Immunology</i> , 2006, 176, 5995-6003.	0.8	8
86	INTERLEUKIN 12 AND INTERFERON- γ SYNTHETIC DEFICIENCY IS ASSOCIATED WITH DENDRITIC CELL CYTOPENIA AFTER CARDIAC SURGERY. <i>Shock</i> , 2005, 24, 26-33.	2.1	11
87	Post-Transplant Administration of Flt3 Ligand Enhances Innate Cellular-Mediated Immune Responses to Toll-Like Receptor Agonists in Syngeneic Bone Marrow Transplant Mice.. <i>Blood</i> , 2005, 106, 5229-5229.	1.4	0
88	Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 834-847.	2.0	21
89	Immune reconstitution in pediatric stem-cell transplantation. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, g23-32.	3.0	7
90	Deactivation of the Innate Cellular Immune Response Following Endotoxic and Surgical Injury. <i>Experimental and Molecular Pathology</i> , 2001, 71, 209-221.	2.1	30

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of atropine-midazolam-ketamine in pediatric oncology patients. Current Therapeutic Research, 1999, 60, 683-693.	1.2	4
92	Improved Hematopoiesis Using Amifostine in Secondary Myelodysplasia. Journal of Pediatric Hematology/Oncology, 1999, 21, 531-534.	0.6	5
93	Infections in Children With Cancer. Journal of Pediatric Hematology/Oncology, 1999, 21, 501-508.	0.6	45